We are live on ! Find out more
ALNY icon

Alnylam Pharmaceuticals

657 hedge funds and large institutions have $43.1B invested in Alnylam Pharmaceuticals in 2025 Q2 according to their latest regulatory filings, with 91 funds opening new positions, 266 increasing their positions, 216 reducing their positions, and 61 closing their positions.

New
Increased
Maintained
Reduced
Closed

49% more first-time investments, than exits

New positions opened: 91 | Existing positions closed: 61

42% more capital inflows, than outflows

Capital inflows: $2.55B | Capital outflows: $1.79B

23% more repeat investments, than reductions

Existing positions increased: 266 | Existing positions reduced: 216

5% more funds holding

Funds holding: 628 → 657 (+29)

1.81% more ownership

Funds ownership: 99.44% → 101.25% (+1.8%)

8% less call options, than puts

Call options by funds: $188M | Put options by funds: $203M

10% less funds holding in top 10

Funds holding in top 10: 10 → 9 (-1)

Holders
657
Holders Change
+29
Holders Change %
+4.62%
% of All Funds
8.61%
Holding in Top 10
9
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-10%
% of All Funds
0.12%
New
91
Increased
266
Reduced
216
Closed
61
Calls
$188​M
Puts
$203​M
Net Calls
-⁠$15.5​M
Net Calls Change
-⁠$50.8​M

ALNY Hedge Fund Activity: Q2 2025 in Review

657 of the 7,630 institutional investors tracked by Wall St. Rank reported a position in Alnylam Pharmaceuticals (ALNY) for Q2 2025, worth a combined $43.1B — up 24% from $34.8B a quarter earlier.

Buyers outnumbered sellers: 91 funds opened new ALNY positions and 61 closed out — a net gain of 30 holders — while 266 added to existing stakes and 216 trimmed.

The largest buyer was Citadel Advisors, adding an estimated $165M. The largest seller was AQR Capital Management, cutting an estimated $177M.

  • 657 institutional investors held Alnylam Pharmaceuticals (ALNY) as of Q2 2025, up from 628 in Q1 2025.
  • Funds reported $43.1B of Alnylam Pharmaceuticals stock for Q2 2025, up 24% quarter-over-quarter.
  • 91 funds opened new Alnylam Pharmaceuticals positions in Q2 2025 and 61 closed out, a net change of +30 holders.
  • The largest Alnylam Pharmaceuticals buyer in Q2 2025 was Citadel Advisors, an estimated $165M added.
  • The largest Alnylam Pharmaceuticals seller in Q2 2025 was AQR Capital Management, an estimated $177M sold.

Based on aggregated 13F filings for Q2 2025.